Menu Search
Equities

Lyell Immunopharma Inc

LYEL:NSQ

Lyell Immunopharma Inc

Actions
  • Price (USD)0.90
  • Today's Change-0.05 / -5.26%
  • Shares traded3.71m
  • 1 Year change-46.43%
  • Beta-0.4649
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lyell Immunopharma Inc's revenues fell -99.85% from 84.68m to 130.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 183.12m to a larger loss of 234.63m.
Gross margin--
Net profit margin-323,792.10%
Operating margin-365,265.10%
Return on assets-28.85%
Return on equity-33.22%
Return on investment-30.32%
More ▼

Cash flow in USDView more

In 2023, Lyell Immunopharma Inc increased its cash reserves by 17.84%, or 22.10m. Cash Flow from Investing totalled 184.05m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 163.69m for operations while cash generated from financing totalled 1.74m.
Cash flow per share-0.7237
Price/Cash flow per share--
Book value per share2.07
Tangible book value per share2.07
More ▼

Balance sheet in USDView more

Lyell Immunopharma Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 145.65m.
Current ratio13.43
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.